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Response to Reviewers’ comments 
 
1. P5, section 2.2: CO2 stimuli are often longer and have multiple blocks. Could 
you comment on the reasons why a shorter duration scan with a single CO2 
block was used here? 
 
Answer:  
Due to the nature of the RespirAct, which allows for a reproducible, standardized 
CO2 stimulus, similar among all subjects, we aimed for a short duration of CO2 
application (ca. 80 seconds), which would still allow for a significant BOLD signal 
change. This approach combines good results with better CO2 tolerability by the 
subjects, due to the shorter CO2 application time (within the physiological range).  
 
 
2. P5, section 2.3: Can you comment on the reasons for applying both low pass 
filtering and the Loess temporal smoothing? Presumably the latter is removing 
low frequency drift, leaving a narrow passband. Is there a risk you are filtering 
out true CO2 stimulus related signal? A simple high pass filter only would give 
me more confidence that this wasn't the case. 
 
Answer:  
It might be, but the high frequency noise will overrun the hypothetical small BOLD 
signal fluctuations when using the high pass filter. 
However, the applied CO2 stimulus is mostly in the low frequency range.  
The interesting part, though, is that the prolonged BOLD signal change is better 
detectable with the robust CO2 stimulus we apply with this novel CO2 technique.  
 
3. P6, section 2.4: Did you apply the same temporal filtering (low pass +Loess) to 
the PetCO2 regressor used to fit the data? Sharp transitions in the BOLD data 
will be lost to the low pass filter, so a better match to the regressor will be 
possible if it similarly filtered. 
 
Answer: 
We obtained the single PetCO2 end-tidal values directly from the RespirAct. We do 
not subtract the entire CO2 curve.  Therefore, this was already a smoothed indication 
from the real trace. As was shown by Slessarev et al [REF], this end tidal tracing 
reflects the arterial partial pressure of CO2 very well. Therefore, we did not apply an 
extra smoothing to PetCO2 tracing. 
 
4. P6, section 2.4: Could you provide a bit more detail on the process to determine 
the "optimal delay" of the regressor with respect to the BOLD data? Were any 
limits imposed on the values that this delay could take and were the resulting 
maps of delay smoothly varying as expected? 
 
Answer: 
Here, we have to redirect the reviewer to our previous paper describing this method in 
detail (van Niftrik, Piccirelli et al 2017). In this particular manuscript we present a 
new method to calculate delay based on the signal changes induced by the BOLD 
signal itself. We direct the method away from a general delay or a delay calculated 
with a maximum correlation. Therefore, the start of the CO2 Bolus coincides with the 
*Detailed Response to Reviewers
start of the BOLD signal changes (positive or negative). For this method, we did not 
apply ranges to our delay calculations. 
 
Changes made to the manuscript: Page 6 section 2.4 
More details are provided in a previous publication by our group. (16) 
 
5. P12, section 4.2: Dampening of the BOLD response was briefly mentioned. Since 
BOLD weighted imaging was used to map CVR this is a point that deserves 
further attention. It's true that CO2 elevation of ICP could reduce the dynamic 
range of the BOLD response. However, other global changes could explain the 
differences observed between patients and controls. The dynamic range of the 
BOLD response is largely determined by the product of venous CBV, oxygen 
extraction fraction (OEF) and haematocrit. Of these, it seems most likely that 
OEF could be disturbed globally in patients, in this case a reduction in OEF. 
This could be caused by either lower oxygen metabolism or increased CBF and 
could be investigated using techniques such as TRUST and ASL, respectively, in 
future work. 
 
Answer: 
Here, we agree with the reviewer that the BOLD signal is dependent of many 
different variables. However, we must mention that a large part of the BOLD signal is 
not just influenced by OEF, CBV or Hematocrit, but also by CBF changes induced by 
the remaining vasodilatory capacity, especially as we use a prospective end tidal gas 
blender, like the RespirAct.  
With a known increased intralesional OEF, the intratumoral CVR should in theory be 
increased as the potential wash-out of deoxyhemoglobin intralesionally is increased. 
However, we find a reduced CVR also intralesional. This makes us believe that the 
vasodilatory capacity (CVR), either through maximal vasodilatation of pre-existing 
vessels or the formation of new vessels - neoangiogenesis – without the capacity of 
vasodilation, has a much larger effect on the BOLD signal intralesional. 
With respect to the global CVR, it is unknown exactly know to what extent all the 
factors influence the BOLD signal. It could be related to a reduction in OEF. That is a 
very exciting research avenue to investigate with either BOLD or other functional 
imaging techniques as mentioned by the reviewer, like ASL and TRUST.  
 
Changes made to the manuscript: Page 11 
Subsequently, with a known increased intralesional Oxygen Extraction Fraction, 
intralesional CVR should theoretically be higher as compared to the whole brain 
CVR, as there should be a higher deoxyhemoglobin content present. With an adequate 
vasodilatory response to a vasodilatory stimulus, the potential wash-out of 
deoxyhemoglobin is increased leading to a higher CVR. However, our findings show 
a more severely impaired intralesional CVR, which makes us believe that the 
vasodilatory capacity has a much larger effect on the BOLD signal intralesional. 
Ideally a multimodal MR imaging protocol, including OEF and CBF measurements, 
might better explain the underlying pathophysiology.  
 
 
 
 
Typos 
 
P2, first paragraph: Is there a word missing in the opening sentence: "Cerebral 
diffuse exhibit perilesional…" 
 
Answer: We have added the word “gliomas” here. This had been erased accidentally.  
 
P5, section 2.2: "build" -> "built" 
 
Answer: This has been changed accordingly.  
 
P7, section 2.6: Last sentence of first paragraph missing full stop. 
 
Answer: corrected accordingly 
 
P11, last paragraph: broken sentence "…whole brain CVR were resp. more and 
equally impaired…" 
Answer: We have revised the sentence. 
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Abstract  
Purpose: Cerebral diffuse gliomas exhibit perilesional impaired cerebrovascular reactivity 
(CVR), yet the degree of impairment as well as its full spatial extent in the brain remains 
unknown. With quantitative fMRI, we studied twelve subjects with untreated brain diffuse 
glioma and twelve healthy controls to assess CVR impairment and determine its distribution 
throughout the brain.  
Methods: In a prospective case-control study, quantitative CVR measurements were derived 
from BOLD fMRI volumes during standardized iso-oxic changes in carbon dioxide. Whole 
brain CVR was assessed with additional detailed analyses using specific tumor and tissue 
masks and compared to datasets of healthy controls.  
Results: Whole brain CVR was significantly impaired compared to healthy controls 
(0.11±0.10 versus 0.28±0.8, p<0.01). All diffuse glioma patients exhibited even more 
severely impaired intralesional CVR (mean 0.01±0.06).  Increasing tumor volume 
significantly correlated with severity of intralesional CVR impairment (p<0.05, R
2
 = 0.38), 
and whole brain CVR impairment (p<0.05, R
2
= 0.55).  
Conclusion: Patients with brain diffuse glioma exhibit intralesional and whole brain impaired 
CVR with severity correlating to tumor volume. Quantitative fMRI may be entertained to 
study antitumor therapy efficacy by tracking CVR changes and may have a complementary 
role to better interpret BOLD associated neurovascular uncoupling. 
 
 
 
 
 
 
 
3 
 
1. Introduction 
Neuroimaging plays a pivotal role in treatment response evaluation of brain diffuse gliomas, 
but is currently limited in accurate depiction of tumor morphology and pathophysiology. (1) 
(2) For instance, contrast enhanced T1-weighted Magnetic Resonance Imaging (CE-MRI) is 
imperfect in identifying true tumor tissue due to heterogeneous contrast enhancement, (3) and 
cannot assess functional parameters such as tumor hemodynamics and molecular 
characteristics. O-(2-[18F]fluoroethyl)-L tyrosine Positron Emission Tomography (FET-PET) 
may potentially provide the best functional imaging information, but heterogeneity in 
(peri)tumor metabolism and long acquisition times may limit clinical applicability. (4) This 
indicates that the complex molecular biology and pathophysiology of brain diffuse glioma 
significantly challenges imaging reliability. 
 
From a hemodynamic perspective, diffuse gliomas are believed to disrupt perivascular 
organization due to co-option of tumor cells accumulating around existing vasculature. (5) As 
a result the blood vessel walls are destabilized with decreased pericyte coverage, cells thought 
to be involved in blood flow autoregulation, (6) leading to inability of viable neurons to 
enhance regional cerebral blood flow (termed `neurovascular uncoupling`) (7-10) a 
phenomenon that may be more pronounced with increasing tumor volume. (11) 
Assessing these alterations of cerebrovascular autoregulation with Blood Oxygen-Level 
Dependent (BOLD) functional (f)MRI cerebrovascular reactivity (CVR) may therefore better 
depict glioma tissue and locate areas of neurovascular uncoupling and tumor-induced 
neuroplasticity, ie. healthy brain tissue with `silenced` viable neurons.(7-9,12) This may 
otherwise manifest itself as false negative activation on conventional task-based BOLD fMRI. 
Our aim therefore was to elaborate on these encouraging first results by others by further 
studying the severity of CVR impairment and its distribution throughout the brain.  
 
4 
 
We prospectively enrolled twelve consecutive subjects harboring untreated brain diffuse 
glioma, and hypothesized that these patients exhibit widespread impaired CVR extending the 
contrast enhancing glioma lesion on T1-weighted MRI. Quantitative CVR was derived from a 
novel standardized BOLD fMRI + CO2 examination (13,14) and compared to matched 
healthy controls undergoing the same protocol. In this study, CVR impairment was present 
over the entire brain in subjects with diffuse glioma.  
 
2. Methods 
The study was approved by the cantonal ethics board of the Canton of Zurich, Switzerland 
(research protocol KEK-ZH-Nr. 2012-0427). Twelve consecutive subjects with newly 
diagnosed and untreated brain diffuse glioma (defined as either WHO Grade III or Grade IV 
as confirmed by histopathological diagnosis) as well as twelve age and sex matched healthy 
controls were prospectively enrolled. Exclusion criteria were the presence of severe 
cardiopulmonary disease, standard MRI contraindications, age<18 years old, or the inability 
or refusal to sign informed consent. Furthermore, healthy controls were screened for no 
medication use, no medical history of neurological disease.  
 
2.1 MRI protocol  
Studies were acquired on a 3 Tesla Skyra VD13 (Siemens, Erlangen, Germany) using a 32-
channel head coil with the following parameters: an axial 2D EPI BOLD fMRI sequence 
planned on the ACPC line plus 20° on a sagittal image with voxel size: 3×3×3 mm
3
, 
acquisition of matrix 64x64x35 slices with ascending interleaved acquisition, slice gap 0.3 
mm, GRAPPA factor 2 with 32 ref. lines, Repetition Time (TR)/TE 2000/30 ms, flip angle 
85°, bandwidth 2368 Hz/Px, Field of View 192x192 mm
2
. Secondly, a high resolution 3D T1-
weighted anatomical image was acquired with the same orientation as the fMRI scan for co-
registration and overlay purposes. The acquisition parameters were: voxel size: 0.8×0.8×1.0 
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mm
3
 with a Field of View 230x230 mm
2
 and resolution of 288x288. 176 slices per slab with a 
thickness of 1 mm, TR/TE 2200/5.14 ms, TI 900 ms, flip angle 8°. The FLAIR images were 
acquired with the same orientation as the BOLD and T1-weighted images. The acquisition 
parameters were as followed 0.9x0.9x1.0 mm
3
 with a Field of View 230x230 mm
2
 and 
resolution of 256x256, 176 slices per slab with a thickness of 1 mm, TR/TE 4000/387 ms, TI 
1800 ms. 
 
2.2 Standardized iso-oxic CO2  stimulus  
All subjects were asked to refrain from caffeine at least 6 hours before scanning. With the use 
of a custom built computer controlled gas blender (RepirAct
TM
, Thornhill Research Institute, 
Toronto, Canada) using the prospective gas targeting algorithms of Slessarev et al. (15), to 
precisely control partial pressure of end-tidal O2 (PETO2) and CO2 (PETCO2). Specific 
improvements and novelties of this technique as compared to other vasoactive stimuli have 
been described in greater detail previously. (13) BOLD signal changes were induced by a 
single hypercapnia pseudo square wave. The pseudo square wave consisted of a hypercapnia 
plateau of 50 mmHg CO2 for 80 seconds following a 100 seconds baseline of 40 mmHg CO2. 
Thereafter, a second baseline of 40 mmHg was maintained for another 100 seconds. During 
the entire protocol iso-oxia (PO2 100 mmHg) was maintained. 
 
2.3 Data analysis of BOLD fMRI and T1-weighted image 
All images were preprocessed using Statistical Parameter Mapping software (SPM 12, 
Wellcome Trust Centre for Neuroimaging, Institute of Neurology, University College 
London; http://www.fil.ion.ucl.ac.uk/spm/). Slice timing correction was applied to correct for 
the interleaved acquisition. The intra fMRI motion was determined and taken out by 
realigning the BOLD images to a mean BOLD volume. Subjects with more than 4mm motion 
were discarded. The T1-weighted image was linearly registered to the mean BOLD volume 
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for optimal alignment. Automated segmentation of the T1-weighted image yielded grey and 
white matter, cerebrospinal fluid, skull and skin probability maps.  The BOLD images were 
spatially smoothed with an 8x8x8-mm
3
 full width half maximum Gaussian kernel. Temporal 
smoothing included a low pass filter of 0.125Hz and robust Loess smoothing (dynamic local 
regression of 6%).  
 
2.4 Cerebrovascular reactivity maps 
MRI volumes were analyzed using MATLAB2013 based (The MathWorks, Inc., Natick, 
United States; (www.matworks.com) in-house written scripts. We determined the optimal 
delay on a voxel-wise basis by applying an iterative analysis to the data to determine the 
correct voxel-wise temporal PETCO2 shift to match the start of the hypercapnia induced 
BOLD signal change. The shifted PETCO2 time series was regressed using a linear least 
square fitting to the BOLD time series on a voxel-per-voxel basis. More details are provided 
in a previous publication by our group. (16) CVR was defined as the %BOLD signal change 
per mmHg CO2. CVR was color-coded between -0.6 and 0.6 and overlaid on the T1 weighted 
image. Only voxels passing a combined grey and white matter probability of 0.9 were 
included for overlay and further analysis (Figure 1). Hemispheres were manually segmented 
in left and right hemisphere and CVR was calculated separately for both.  
 
2.5 Tumor and edema mask determination 
The tumor mask was determined by a senior staff neuroradiologist (A.P.). Here, the mask was 
determined from a contrast enhanced T1-weighted anatomical volume where the contrast-
enhancing lesion was depicted. This mask was used to determine intralesional CVR and 
tumor volume. Intralesional CVR was calculated by projecting the tumor mask on the CVR 
map (Figure 1). This tumor mask was also mirrored onto the ‘unaffected’ contralateral 
hemisphere (excluding the gliomas with a “butterfly” configuration, n= 8) for subsequent 
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CVR comparison. Regarding this mask only voxels within the grey and white matter were 
considered for further analysis. Extent of edema was determined and masked using a high 
resolution FLAIR T2 weighted image. Tumor volume was based on MR voxel proportions 
and number of voxels within the tumor and calculated in mm
3
.  
 
2.6 Statistical Analysis 
Continuous variables are presented as mean ± standard deviation. Demographic data and CVR 
were compared between two groups (diffuse glioma patients versus healthy controls) using 
independent sample t-tests and Fisher’s Exact test [p<0.05 was considered significant; t(24) = 
2.064]. Comparison between the ipsilateral and contralateral tumor masks were done using a 
paired sample T Test. 
As a sub-analysis mean CVR of subjects with grade III and grade IV were compared. 
Comparisons between groups were done using the Chi-square test or the Fisher’s exact test, 
where appropriate. To corroborate the results of bivariate testing, we constructed a 
generalized linear model with tumor volume as the independent variable.  
 
 
3. Results 
3.1 Potential confounders affecting CVR measurements in the study cohort 
We assessed several comorbidities that could potentially affect CVR findings, such as 
diabetes, smoking, chronic obstructive pulmonary disease, asthma, hypercholesteremia and 
hypertension. These did not reveal significant differences in CVR readings between patients 
with diffuse glioma and healthy controls (p= 0.45). Furthermore, since target PETCO2 and 
PETO2 were controlled no significant differences between patients and controls were found for 
baseline conditions (40.3±1.3 versus 40.5±1.3, p= 0.55, respectively), hypercapnia (50 ± 1.4 
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versus 48.2±1.2, p= 0.43 respectively) and CO2 step change (p= 0.48).  End tidal PCO2 
(PETCO2) and PO2 (PETO2) values for patients are shown in Table 1. 
 
3.2 CVR findings in patients with diffuse glioma and healthy references 
To examine whether diffuse glioma impacts cerebrovascular reactivity, we analyzed CVR 
maps of 12 patients with diffuse glioma (mean age 50 years,  range 27-81; 4 females) and 
compared these to CVR maps of 12 age and sex matched healthy controls. More detailed 
patient and tumor characteristics are shown in Table 1. Differences in CVR were calculated as 
the percent change in BOLD signal per mmHg change in PETCO2 (see Methods section). 
Whole brain CVR of diffuse glioma patients was significantly impaired compared to healthy 
controls (0.11±0.10 versus 0.28±0.8, p<0.01; Figure 2 & Table 2).  Additionally, individual 
CVR measurements of both hemispheres, ipsi- and contralateral, were also significantly 
impaired as opposed to healthy controls (p<0.05). This suggests that diffuse glioma impacts 
CVR on a widespread scale.  
 
3.3 CVR findings in patients with diffuse glioma 
Further detailed analyses were done on diffuse glioma patients. Ipsilateral CVR was 
significantly more impaired as compared to contralateral CVR (0.10±0.9 vs 0.13±0.9, 
p<0.01). All diffuse glioma patients exhibited intralesional impaired CVR with an overall 
mean of 0.01±0.06, which was significantly decreased as compared to whole brain CVR 
(p<0.05). By flipping the tumor mask onto the contralateral hemisphere, a mirror CVR 
comparison was done (0.07±0.06) which confirmed a significant impaired CVR within the 
tumor (p<0.05).  
Perifocal edema was determined from a T2-FLAIR volume (see methods) and subsequently 
analyzed for CVR. This also demonstrated impaired CVR (0.04±0.05), however intralesional 
CVR was again more impaired (p<0.05). A trend in correlation was observed towards more 
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severe intralesional and whole brain CVR impairment in WHO grade IV gliomas (grade III 
(n= 6) versus grade IV (n= 6); 0.12±0.13 vs 0.10±0.07 p=0.77 for whole brain CVR; 0.0±0.06 
vs 0.03±0.06 p =0.42 for intralesional CVR). Tumor volume was not a confounder in this 
analysis. This may actually reach statistical significance in a future, larger series of patients. 
The significantly impaired CVR findings in patients with diffuse glioma are plotted in Figure 
3 for visual appreciation, against a reference CVR value derived from the cohort of healthy 
subjects. In the supplementary files we have added a movie of whole brain CVR in 1) a 
healthy subject (Supporting Video S1) and 1) a patient with a diffuse glioma (Supporting 
Video S2).  
 
3.4 Correlation of CVR impairment versus tumor volume 
Since all diffuse glioma patients exhibited whole brain and intralesional CVR impairment, for 
our final analysis, we determined the association of tumor volume with degree of CVR 
impairment.  Here, severity of intralesional CVR impairment was significantly correlated to 
tumor volume (p<0.05, R
2
 = 0.38, Figure 4). This correlation was even stronger between 
whole brain CVR and tumor volume (p<0.05, R
2
= 0.55, Figure 4).  
 
 
4. Discussion 
Quantitative CVR obtained with standardized BOLD fMRI + CO2 highlights extensive 
impairment in brain diffuse glioma. All 12 glioma patients exhibited whole brain impaired 
CVR, and to a greater extent intralesional impaired CVR. Interestingly, a trend was observed 
towards more severe CVR impairment in glioblastoma (WHO grade IV) patients.  
Important to mention is that our data confirm previous findings of intralesional CVR 
impairment, (7,8,12,17) and that we newly demonstrate presence of CVR impairment in the 
entire brain with severity correlating to tumor volume. This global presence of impaired CVR 
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warrants current findings of BOLD fMRI associated perilesional neurovascular uncoupling 
and tumor-induced neuroplasticity in cerebral diffuse gliomas. Pillai et al. (18,19) have 
already advocated the importance of a complementary BOLD CVR examination to validate 
perilesional neurovascular uncoupling, ie. to correct for false negative activation on 
conventional task-based fMRI. Furthermore, even though the presence of tumor-induced 
neuroplasticity has univocally been proven by itself, detecting such with BOLD fMRI may 
have to be interpreted with caution as presence of CVR impairment may also lead to false 
negative BOLD signal changes. For instance, Southwell et al. (20) measured “less functional 
reorganization” in patients with larger volume diffuse gliomas. Following this observation 
Wang et al. (11) have shown that neurovascular uncoupling is more pronounced with 
increasing tumor volume. Both observations confirm that caution must be taken to interpret 
these data as increasing CVR impairment may partially influence the readout.  
Furthermore, these effects may not be limited solely to the perilesional tissue and our current 
findings underscore the importance of obtaining a quantitative CVR map of the entire brain in 
order to better validate the presence of BOLD associated neurovascular uncoupling and tumor 
induced neuroplasticity.  
 
The exact pathophysiological mechanisms causing this vascular dysregulation appear to be 
complex and remain to be further elucidated. Animal studies in diffuse glioma have indicated 
smooth muscle vascular tone disruption due to displacement of astrocyte end-feet covering 
the vascular surface, ie. tumor cell co-option. (5) As a result the blood vessel walls are 
destabilized with decreased pericyte coverage, cells thought to be involved in CBF 
autoregulation, (6) leading to inability of viable neurons to enhance regional blood flow. This 
vascular dysregulation can be a reason for impaired CVR due to altered autoregulation. A 
second reason may be abnormal neoangiogenesis following increased tumor metabolism, 
which often results in angioarchitecture lacking smooth muscle cells and vessels therefore are 
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not able to respond appropriately to a CO2 stimulus. (21) In this instance, surrounding healthy 
tissue can still vasodilate (ie. drop vascular resistance) and will redirect blood flow away from 
the non-responsive abnormal vessels. Indeed, clinical studies have found that a CO2 stimulus 
results in redistribution of cerebral blood flow (CBF) from a tumor region with abnormal 
angiogenesis to a responsive tumor region and surrounding normal tissue, causing a focal 
steal phenomenon (ie. severely impaired CVR). (12) In contrast, steal phenomenon has not 
been found in patients harboring low grade gliomas.(12,22) Finally, locally impaired CVR 
may also be related to mass effect of the tumor on surrounding healthy tissue. The resulting 
perifocal pressure may alter cerebrovascular autoregulation. Sharma et al. (23) found that 
CVR impairment was associated with tumor size and midline shift >5mm. Although none of 
our subjects exhibited acute clinical signs of raised intracranial pressure, mass effect may 
have indeed contributed to a decreased BOLD signal. This pressure effect can involve the 
entire brain with increasing tumor volume. In larger tumors, CBF recruitment may exceed the 
capacity of CVR of the perilesional tissue and therefore impact on the entire brain. The 
presence of whole brain impaired CVR for such lesions indicates adjustment of healthy blood 
vessels, ie. dropping vascular resistance in order to compete for adequate blood flow supply. 
Subsequently, with a known increased intralesional Oxygen Extraction Fraction (OEF), 
intralesional CVR should theoretically be higher as compared to the whole brain CVR, as 
there should be a higher deoxyhemoglobin content present. With an adequate vasodilatory 
response to a vasodilatory stimulus, the potential wash-out of deoxyhemoglobin is increased 
leading to a higher CVR. However, our findings show a more severely impaired intralesional 
CVR, which makes us believe that the vasodilatory capacity has a much larger effect on the 
BOLD signal intralesional. 
Ideally a multimodal MR imaging protocol, including OEF and CBF measurements, might 
better explain the underlying pathophysiology.  
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Lastly, impaired CVR was also found within the perifocal edema. A report by Ludemann et 
al. (22) showed that the presence of perifocal edema does not influence CVR measurements 
obtained with BOLD fMRI, but this finding was based on a small cohort and has not been 
reproduced. Although we believe that edema may have contributed to perilesional CVR 
impairment, the fact that intralesional CVR was more severely impaired as compared to 
whole brain CVR shows that this effect may not be significant. The true influence of edema 
on perilesional CVR will have to be further studied with more detailed analyses.  
 
4.1 Obtaining CVR measurements 
The major challenge for quantifying CVR is the inherent limitation of applying a standardized 
(vaso)active stimulus in order to reliably and sensitively detect CVR abnormalities. (13) Most 
studies therefore determine breath-hold based CVR to assess impaired (peri-)lesional CVR by 
comparing CVR values to the assumingly healthy contralateral hemisphere. 
(7,12,21,22,24,25) Our data, however, demonstrate that quantitative CVR measurements also 
reveal substantially impaired CVR in the contralateral hemisphere. A finding that has been 
confirmed recently by Sam et al. (26) using the same technique. Therefore, breath-hold based 
CVR calculations may lead to type II statistical error.  
For over ten years, we have been successfully employing standardized prospective CO2 
targeting for our BOLD related CVR studies (27,28) and have implemented the same protocol 
for this study with improved methodological CVR analysis. (16) This has resulted in a 
quantitative and sensitive (voxel-wise) whole brain CVR analysis in patients with diffuse 
gliomas. The use of a `healthy` contralateral hemisphere or ROI may also be argued based on 
these data, since all of our subjects exhibited impaired CVR contralaterally. Although a 
relative CVR difference may be calculated from a contralateral hemisphere or ROI, using the 
term healthy may be erroneous. A comparison against a statistical control atlas containing 
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data of healthy volunteers may therefore provide a more sensitive and reliable quantitative 
measure to assess the degree of CVR impairment. (29) 
 
4.2 Limitations  
Theoretically, impaired CVR may have been the consequence of a `dampened` BOLD 
response by CO2 elevations or raised intracranial pressure (ICP) as a result of tumor mass 
including perifocal edema. (23,30) Although the CVR findings appear to discriminate 
between patients with diffuse glioma and healthy controls, possible confounders such as co-
morbidities and glioma characteristics, might have influenced CVR readings. Even though 
these features did not demonstrate a statistically significant effect, these analyses are 
underpowered to reveal possible statistical differences in our cohort, with a relatively small 
sample size of 24 subjects. In addition, the effect of age, pulmonary disease and history of 
chronic cigarette smoking, which may ordinarily increase the arterial to end-tidal gradient in 
spontaneously breathing subjects, might influence CVR readings. However, Ito et al. (31) 
have argued that, with computer controlled prospective end-tidal targeting, the gradient will 
nevertheless, be small, even in the presence of lung disease, over a large range of induced 
PCO2 and O2 pressure. 
 
5. Conclusion 
Patients with brain diffuse glioma exhibit intralesional and whole brain impaired CVR with 
severity correlating to tumor volume. A quantitative whole brain CVR evaluation may have a 
complementary role to better assess BOLD associated neurovascular uncoupling.  
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Figure 1: Illustrative example of cerebrovascular reactivity map and tumor mask 
Caption: Axial projected T1-weighted images demonstrating a glioblastoma WHO grade IV 
in the left frontal region (left upper images, non-contrast and contrast-enhanced T1-weighted 
images) which was subsequently masked by a staff neuroradiologist (A.P.; lower left image), 
to determine CVR in that region (far right images). The tumor masked was subsequently 
flipped in order to determine contralateral CVR in the same region. A separate edema mask 
was created to specifically measure CVR in that region (the tumor mask was subtracted from 
the edema mask to determine CVR in the edema region). CVR ranges from normal reactivity 
(red) to impaired reactivity (yellow-green) to steal phenomenon (blue).  
  
Figure 2: Exemplary cases demonstrating severity of cerebrovascular reactivity 
impairment 
Caption: Axial projected T1-weighted anatomical images and subsequent CVR overlays 
showing a CVR map of a healthy subject (A), and two patients with diffuse glioma (B & C). 
Note that the larger tumor lesion (C) exhibits more severely impaired CVR extending over the 
entire brain. CVR ranges from normal reactivity (red) to impaired reactivity (yellow-green) to 
steal phenomenon (blue).  
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Figure 3: Boxplots of CVR findings in healthy subjects and diffuse glioma patients 
Box-whisker plots of whole brain CVR, intralesional CVR and CVR measured in perilesional 
edema (Figure 3A). On the left is whole brain CVR derived from 12 healthy subjects 
depicted, as a reference. All three aforementioned CVR values (tumor whole brain, 
intralesional and edema) are significantly lower as compared to the healthy CVR (indicated 
with * * *; p<0.01). CVR intralesional as well as CVR edema are also significantly lower as 
compared to whole brain tumor CVR (p<0.05). Figure 3B shows a significantly lower CVR 
for the tumor mask as compared to the same masked flipped onto the contralateral hemisphere 
(p<0.05).  
  
Figure 4: Correlation between cerebrovascular reactivity impairment and tumor volume 
Caption: Graphic representation of the tumor volume plotted versus degree of CVR 
impairment for whole brain (A) and intralesional CVR (B). Both analyses showed a 
significant correlation (p<0.05, R
2
= 0.80 and p<0.05, R
2
 = 0.50, respectively). The dotted red 
line in Figure 4A indicates normal mean quantitative CVR calculated from the 12 healthy 
subjects.  
Abbreviations: WB = whole brain 
 
Supplementary material  
Caption: Supporting Video S1illustrates whole brain normal CVR. Supporting Video S2 
illustrates whole brain impaired CVR in a patient with diffuse glioma (specifically a butterfly 
glioblastoma WHO Grad IV). CVR ranges from normal reactivity (red) to impaired reactivity 
(yellow-green) to steal phenomenon (blue). 
 
Table 1: Patient and tumor characteristics 
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Table 2: CVR findings and tumor volume 
  
CVR (% BOLD signal change/ mmHg CO2) 
Subject 
 Whole 
brain 
Affected 
hemisphere 
Unaffected 
hemisphere intralesional 
Volume 
(cm3) 
1 0.17 0.16 0.18 0.04 47.06 
2 0.22 0.22 0.22 0.17 14.76 
3 0.17 0.13 0.17 0.02 7.79 
4 0.23 0.23 0.25 0.06 2.62 
5 -0.08 -0.09 -0.05 -0.06 144.69 
6 -0.01 -0.02 0.03 -0.07 51.76 
7 0.01 -0.01 0.02 -0.04 119.4 
8 0.1 0.1 0.08 0.02 17.6 
9 0.18 0.1 0.14 0.03 43 
10 0.2 0.16 0.23 0.12 28.55 
11 0.13 0.11 0.14 0.05 77.22 
12 0.04 0.09 0.1 0.01 40.44 
Mean(± SD) 
0.11 (0.10) 0.10 (0.10) 0.13 (0.09) 0.03 (0.07) 
49.57 
(0.16) 
 
Subject Age Sex Histology WHO Grade Tumor location  Clinical presentation CO2 baseline (calibrated) CO2 Hypercapnia
1 49 F Oligoastrocytoma III right frontal Epilepsy 39 48
2 39 M Oligoastrocytoma III left frontal Epilepsy 42 49
3 54 F Oligoastrocytoma III left frontal Headache, aphasia 41 51
4 32 F Anaplastic astrocytoma III right temporal Headache 41 51
5 50 M Oligodendroglioma III bifrontal Headache, Neuropsychological deficits 42 52
6 27 M Astrocytoma III right frontal Epilepsy 41 50
7 66 M Glioblastoma IV bifrontal Neuropsychological deficits 38 49
8 81 M Glioblastoma IV left temporal Aphasia 40 50
9 64 M Glioblastoma IV bifrontal Headache, Neuropsychological deficits 40 51
10 64 F Glioblastoma IV left parieto-occip Epilepsy, hemianopsia 40 50
11 91 M Glioblastoma IV right temporal Headache, vertigo 40 50
12 78 M Glioblastoma IV left frontal Psychomotoric deficits 40 50
1 
 
Title: Diffuse gliomas exhibit whole brain impaired cerebrovascular reactivity 
 
Running Title: Diffuse gliomas exhibit impaired CVR  
 
Authors: Jorn Fierstra, MD PhD
1
; Christiaan van Niftrik, MD
1
; Marco Piccirelli, PhD
2
; 
Oliver Bozinov, MD
1
; Athina Pangalu, MD
2
; Niklaus Krayenbühl, MD
1
; Antonios Valavanis, 
MD
2
; Michael Weller, MD
3
; Luca Regli MD
1
        
 
Affiliations: Departments of Neurosurgery
1
, Neuroradiology
2
, and Neurology
3
, Clinical 
Neuroscience Center, University Hospital Zurich, University of Zurich, Switzerland 
 
Corresponding author 
Jorn Fierstra, MD PhD 
Department of Neurosurgery, University Hospital Zurich 
Frauenklinikstrasse 10, 8091 Zurich, Switzerland  
Phone: +41-44-2551111, Fax: +41-44-2554505 E-mail: jorn.fierstra@usz.ch  
 
 
Keywords: fMRI, BOLD, diffuse glioma, cerebrovascular reactivity, carbon dioxide  
 
 
 
 
 
 
 
*Manuscript trckchngs
Click here to view linked References
2 
 
Abstract  
Purpose: Cerebral diffuse gliomas exhibit perilesional impaired cerebrovascular reactivity 
(CVR), yet the degree of impairment as well as its full spatial extent in the brain remains 
unknown. With quantitative fMRI, we studied twelve subjects with untreated brain diffuse 
glioma and twelve healthy controls to assess CVR impairment and determine its distribution 
throughout the brain.  
Methods: In a prospective case-control study, quantitative CVR measurements were derived 
from BOLD fMRI volumes during standardized iso-oxic changes in carbon dioxide. Whole 
brain CVR was assessed with additional detailed analyses using specific tumor and tissue 
masks and compared to datasets of healthy controls.  
Results: Whole brain CVR was significantly impaired compared to healthy controls 
(0.11±0.10 versus 0.28±0.8, p<0.01). All diffuse glioma patients exhibited even more 
severely impaired intralesional CVR (mean 0.01±0.06).  Increasing tumor volume 
significantly correlated with severity of intralesional CVR impairment (p<0.05, R
2
 = 0.38), 
and whole brain CVR impairment (p<0.05, R
2
= 0.55).  
Conclusion: Patients with brain diffuse glioma exhibit intralesional and whole brain impaired 
CVR with severity correlating to tumor volume. Quantitative fMRI may be entertained to 
study antitumor therapy efficacy by tracking CVR changes and may have a complementary 
role to better interpret BOLD associated neurovascular uncoupling. 
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1. Introduction 
Neuroimaging plays a pivotal role in treatment response evaluation of brain diffuse gliomas, 
but is currently limited in accurate depiction of tumor morphology and pathophysiology. (1) 
(2) For instance, contrast enhanced T1-weighted Magnetic Resonance Imaging (CE-MRI) is 
imperfect in identifying true tumor tissue due to heterogeneous contrast enhancement, (3) and 
cannot assess functional parameters such as tumor hemodynamics and molecular 
characteristics. O-(2-[18F]fluoroethyl)-L tyrosine Positron Emission Tomography (FET-PET) 
may potentially provide the best functional imaging information, but heterogeneity in 
(peri)tumor metabolism and long acquisition times may limit clinical applicability. (4) This 
indicates that the complex molecular biology and pathophysiology of brain diffuse glioma 
significantly challenges imaging reliability. 
 
From a hemodynamic perspective, diffuse gliomas are believed to disrupt perivascular 
organization due to co-option of tumor cells accumulating around existing vasculature. (5) As 
a result the blood vessel walls are destabilized with decreased pericyte coverage, cells thought 
to be involved in blood flow autoregulation, (6) leading to inability of viable neurons to 
enhance regional cerebral blood flow (termed `neurovascular uncoupling`) (7-10) a 
phenomenon that may be more pronounced with increasing tumor volume. (11) 
Assessing these alterations of cerebrovascular autoregulation with Blood Oxygen-Level 
Dependent (BOLD) functional (f)MRI cerebrovascular reactivity (CVR) may therefore better 
depict glioma tissue and locate areas of neurovascular uncoupling and tumor-induced 
neuroplasticity, ie. healthy brain tissue with `silenced` viable neurons.(7-9,12) This may 
otherwise manifest itself as false negative activation on conventional task-based BOLD fMRI. 
Our aim therefore was to elaborate on these encouraging first results by others by further 
studying the severity of CVR impairment and its distribution throughout the brain.  
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We prospectively enrolled twelve consecutive subjects harboring untreated brain diffuse 
glioma, and hypothesized that these patients exhibit widespread impaired CVR extending the 
contrast enhancing glioma lesion on T1-weighted MRI. Quantitative CVR was derived from a 
novel standardized BOLD fMRI + CO2 examination (13,14) and compared to matched 
healthy controls undergoing the same protocol. In this study, CVR impairment was present 
over the entire brain in subjects with diffuse glioma.  
 
2. Methods 
The study was approved by the cantonal ethics board of the Canton of Zurich, Switzerland 
(research protocol KEK-ZH-Nr. 2012-0427). Twelve consecutive subjects with newly 
diagnosed and untreated brain diffuse glioma (defined as either WHO Grade III or Grade IV 
as confirmed by histopathological diagnosis) as well as twelve age and sex matched healthy 
controls were prospectively enrolled. Exclusion criteria were the presence of severe 
cardiopulmonary disease, standard MRI contraindications, age<18 years old, or the inability 
or refusal to sign informed consent. Furthermore, healthy controls were screened for no 
medication use, no medical history of neurological disease.  
 
2.1 MRI protocol  
Studies were acquired on a 3 Tesla Skyra VD13 (Siemens, Erlangen, Germany) using a 32-
channel head coil with the following parameters: an axial 2D EPI BOLD fMRI sequence 
planned on the ACPC line plus 20° on a sagittal image with voxel size: 3×3×3 mm
3
, 
acquisition of matrix 64x64x35 slices with ascending interleaved acquisition, slice gap 0.3 
mm, GRAPPA factor 2 with 32 ref. lines, Repetition Time (TR)/TE 2000/30 ms, flip angle 
85°, bandwidth 2368 Hz/Px, Field of View 192x192 mm
2
. Secondly, a high resolution 3D T1-
weighted anatomical image was acquired with the same orientation as the fMRI scan for co-
registration and overlay purposes. The acquisition parameters were: voxel size: 0.8×0.8×1.0 
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mm
3
 with a Field of View 230x230 mm
2
 and resolution of 288x288. 176 slices per slab with a 
thickness of 1 mm, TR/TE 2200/5.14 ms, TI 900 ms, flip angle 8°. The FLAIR images were 
acquired with the same orientation as the BOLD and T1-weighted images. The acquisition 
parameters were as followed 0.9x0.9x1.0 mm
3
 with a Field of View 230x230 mm
2
 and 
resolution of 256x256, 176 slices per slab with a thickness of 1 mm, TR/TE 4000/387 ms, TI 
1800 ms. 
 
2.2 Standardized iso-oxic CO2  stimulus  
All subjects were asked to refrain from caffeine at least 6 hours before scanning. With the use 
of a custom builtd computer controlled gas blender (RepirAct
TM
, Thornhill Research Institute, 
Toronto, Canada) using the prospective gas targeting algorithms of Slessarev et al. (15), to 
precisely control partial pressure of end-tidal O2 (PETO2) and CO2 (PETCO2). Specific 
improvements and novelties of this technique as compared to other vasoactive stimuli have 
been described in greater detail previously. (13) BOLD signal changes were induced by a 
single hypercapnia pseudo square wave. The pseudo square wave consisted of a hypercapnia 
plateau of 50 mmHg CO2 for 80 seconds following a 100 seconds baseline of 40 mmHg CO2. 
Thereafter, a second baseline of 40 mmHg was maintained for another 100 seconds. During 
the entire protocol iso-oxia (PO2 100 mmHg) was maintained. 
 
2.3 Data analysis of BOLD fMRI and T1-weighted image 
All images were preprocessed using Statistical Parameter Mapping software (SPM 12, 
Wellcome Trust Centre for Neuroimaging, Institute of Neurology, University College 
London; http://www.fil.ion.ucl.ac.uk/spm/). Slice timing correction was applied to correct for 
the interleaved acquisition. The intra fMRI motion was determined and taken out by 
realigning the BOLD images to a mean BOLD volume. Subjects with more than 4mm motion 
were discarded. The T1-weighted image was linearly registered to the mean BOLD volume 
Field Code Changed
Field Code Changed
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for optimal alignment. Automated segmentation of the T1-weighted image yielded grey and 
white matter, cerebrospinal fluid, skull and skin probability maps.  The BOLD images were 
spatially smoothed with an 8x8x8-mm
3
 full width half maximum Gaussian kernel. Temporal 
smoothing included a low pass filter of 0.125Hz and robust Loess smoothing (dynamic local 
regression of 6%).  
 
2.4 Cerebrovascular reactivity maps 
MRI volumes were analyzed using MATLAB2013 based (The MathWorks, Inc., Natick, 
United States; (www.matworks.com) in-house written scripts. We determined the optimal 
delay on a voxel-wise basis by applying an iterative analysis to the data to determine the 
correct voxel-wise temporal PETCO2 shift to match the start of the hypercapnia induced 
BOLD signal change. The shifted PETCO2 time series was regressed using a linear least 
square fitting to the BOLD time series on a voxel-per-voxel basis. More details are provided 
in a previous publication by our group. (16) CVR was defined as the %BOLD signal change 
per mmHg CO2. (16) CVR was color-coded between -0.6 and 0.6 and overlaid on the T1 
weighted image. Only voxels passing a combined grey and white matter probability of 0.9 
were included for overlay and further analysis (Figure 1). Hemispheres were manually 
segmented in left and right hemisphere and CVR was calculated separately for both.  
 
2.5 Tumor and edema mask determination 
The tumor mask was determined by a senior staff neuroradiologist (A.P.). Here, the mask was 
determined from a contrast enhanced T1-weighted anatomical volume where the contrast-
enhancing lesion was depicted. This mask was used to determine intralesional CVR and 
tumor volume. Intralesional CVR was calculated by projecting the tumor mask on the CVR 
map (Figure 1). This tumor mask was also mirrored onto the ‘unaffected’ contralateral 
hemisphere (excluding the gliomas with a “butterfly” configuration, n= 8) for subsequent 
Formatted: Justified
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CVR comparison. Regarding this mask only voxels within the grey and white matter were 
considered for further analysis. Extent of edema was determined and masked using a high 
resolution FLAIR T2 weighted image. Tumor volume was based on MR voxel proportions 
and number of voxels within the tumor and calculated in mm
3
.  
 
2.6 Statistical Analysis 
Continuous variables are presented as mean ± standard deviation. Demographic data and CVR 
were compared between two groups (diffuse glioma patients versus healthy controls) using 
independent sample t-tests and Fisher’s Exact test [p<0.05 was considered significant; t(24) = 
2.064]. Comparison between the ipsilateral and contralateral tumor masks were done using a 
paired sample T Test. 
As a sub-analysis mean CVR of subjects with grade III and grade IV were compared. 
Comparisons between groups were done using the Chi-square test or the Fisher’s exact test, 
where appropriate. To corroborate the results of bivariate testing, we constructed a 
generalized linear model with tumor volume as the independent variable.  
 
 
3. Results 
3.1 Potential confounders affecting CVR measurements in the study cohort 
We assessed several comorbidities that could potentially affect CVR findings, such as 
diabetes, smoking, chronic obstructive pulmonary disease, asthma, hypercholesteremia and 
hypertension. These did not reveal significant differences in CVR readings between patients 
with diffuse glioma and healthy controls (p= 0.45). Furthermore, since target PETCO2 and 
PETO2 were controlled no significant differences between patients and controls were found for 
baseline conditions (40.3±1.3 versus 40.5±1.3, p= 0.55, respectively), hypercapnia (50 ± 1.4 
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versus 48.2±1.2, p= 0.43 respectively) and CO2 step change (p= 0.48).  End tidal PCO2 
(PETCO2) and PO2 (PETO2) values for patients are shown in Table 1. 
 
3.2 CVR findings in patients with diffuse glioma and healthy references 
To examine whether diffuse glioma impacts cerebrovascular reactivity, we analyzed CVR 
maps of 12 patients with diffuse glioma (mean age 50 years,  range 27-81; 4 females) and 
compared these to CVR maps of 12 age and sex matched healthy controls. More detailed 
patient and tumor characteristics are shown in Table 1. Differences in CVR were calculated as 
the percent change in BOLD signal per mmHg change in PETCO2 (see Methods section). 
Whole brain CVR of diffuse glioma patients was significantly impaired compared to healthy 
controls (0.11±0.10 versus 0.28±0.8, p<0.01; Figure 2 & Table 2).  Additionally, individual 
CVR measurements of both hemispheres, ipsi- and contralateral, were also significantly 
impaired as opposed to healthy controls (p<0.05). This suggests that diffuse glioma impacts 
CVR on a widespread scale.  
 
3.3 CVR findings in patients with diffuse glioma 
Further detailed analyses were done on diffuse glioma patients. Ipsilateral CVR was 
significantly more impaired as compared to contralateral CVR (0.10±0.9 vs 0.13±0.9, 
p<0.01). All diffuse glioma patients exhibited intralesional impaired CVR with an overall 
mean of 0.01±0.06, which was significantly decreased as compared to whole brain CVR 
(p<0.05). By flipping the tumor mask onto the contralateral hemisphere, a mirror CVR 
comparison was done (0.07±0.06) which confirmed a significant impaired CVR within the 
tumor (p<0.05).  
Perifocal edema was determined from a T2-FLAIR volume (see methods) and subsequently 
analyzed for CVR. This also demonstrated impaired CVR (0.04±0.05), however intralesional 
CVR was again more impaired (p<0.05). A trend in correlation was observed towards more 
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severe intralesional and whole brain CVR impairment in WHO grade IV gliomas (grade III 
(n= 6) versus grade IV (n= 6); 0.12±0.13 vs 0.10±0.07 p=0.77 for whole brain CVR; 0.0±0.06 
vs 0.03±0.06 p =0.42 for intralesional CVR). Tumor volume was not a confounder in this 
analysis. This may actually reach statistical significance in a future, larger series of patients. 
The significantly impaired CVR findings in patients with diffuse glioma are plotted in Figure 
3 for visual appreciation, against a reference CVR value derived from the cohort of healthy 
subjects. In the supplementary files we have added a movie of whole brain CVR in 1) a 
healthy subject (Supporting Video S1) and 1) a patient with a diffuse glioma (Supporting 
Video S2).  
 
3.4 Correlation of CVR impairment versus tumor volume 
Since all diffuse glioma patients exhibited whole brain and intralesional CVR impairment, for 
our final analysis, we determined the association of tumor volume with degree of CVR 
impairment.  Here, severity of intralesional CVR impairment was significantly correlated to 
tumor volume (p<0.05, R
2
 = 0.38, Figure 4). This correlation was even stronger between 
whole brain CVR and tumor volume (p<0.05, R
2
= 0.55, Figure 4).  
 
 
4. Discussion 
Quantitative CVR obtained with standardized BOLD fMRI + CO2 highlights extensive 
impairment in brain diffuse glioma. All 12 glioma patients exhibited whole brain impaired 
CVR, and to a greater extent intralesional impaired CVR. Interestingly, a trend was observed 
towards more severe CVR impairment in glioblastoma (WHO grade IV) patients.  
Important to mention is that our data confirm previous findings of intralesional CVR 
impairment, (7,8,12,17) and that we newly demonstrate presence of CVR impairment in the 
entire brain with severity correlating to tumor volume. This global presence of impaired CVR 
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warrants current findings of BOLD fMRI associated perilesional neurovascular uncoupling 
and tumor-induced neuroplasticity in cerebral diffuse gliomas. Pillai et al. (18,19) have 
already advocated the importance of a complementary BOLD CVR examination to validate 
perilesional neurovascular uncoupling, ie. to correct for false negative activation on 
conventional task-based fMRI. Furthermore, even though the presence of tumor-induced 
neuroplasticity has univocally been proven by itself, detecting such with BOLD fMRI may 
have to be interpreted with caution as presence of CVR impairment may also lead to false 
negative BOLD signal changes. For instance, Southwell et al. (20) measured “less functional 
reorganization” in patients with larger volume diffuse gliomas. Following this observation 
Wang et al. (11) have shown that neurovascular uncoupling is more pronounced with 
increasing tumor volume. Both observations confirm that caution must be taken to interpret 
these data as increasing CVR impairment may partially influence the readout.  
Furthermore, these effects may not be limited solely to the perilesional tissue and our current 
findings underscore the importance of obtaining a quantitative CVR map of the entire brain in 
order to better validate the presence of BOLD associated neurovascular uncoupling and tumor 
induced neuroplasticity.  
 
The exact pathophysiological mechanisms causing this vascular dysregulation appear to be 
complex and remain to be further elucidated. Animal studies in diffuse glioma have indicated 
smooth muscle vascular tone disruption due to displacement of astrocyte end-feet covering 
the vascular surface, ie. tumor cell co-option. (5) As a result the blood vessel walls are 
destabilized with decreased pericyte coverage, cells thought to be involved in CBF 
autoregulation, (6) leading to inability of viable neurons to enhance regional blood flow. This 
vascular dysregulation can be a reason for impaired CVR due to altered autoregulation. A 
second reason may be abnormal neoangiogenesis following increased tumor metabolism, 
which often results in angioarchitecture lacking smooth muscle cells and vessels therefore are 
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not able to respond appropriately to a CO2 stimulus. (21) In this instance, surrounding healthy 
tissue can still vasodilate (ie. drop vascular resistance) and will redirect blood flow away from 
the non-responsive abnormal vessels. Indeed, clinical studies have found that a CO2 stimulus 
results in redistribution of cerebral blood flow (CBF) from a tumor region with abnormal 
angiogenesis to a responsive tumor region and surrounding normal tissue, causing a focal 
steal phenomenon (ie. severely impaired CVR). (12) In contrast, steal phenomenon has not 
been found in patients harboring low grade gliomas.(12,22) Finally, locally impaired CVR 
may also be related to mass effect of the tumor on surrounding healthy tissue. The resulting 
perifocal pressure may alter cerebrovascular autoregulation. Sharma et al. (23) found that 
CVR impairment was associated with tumor size and midline shift >5mm. Although none of 
our subjects exhibited acute clinical signs of raised intracranial pressure, mass effect may 
have indeed contributed to a decreased BOLD signal. This pressure effect can involve the 
entire brain with increasing tumor volume. In larger tumors, CBF recruitment may exceed the 
capacity of CVR of the perilesional tissue and therefore impact on the entire brain. The 
presence of whole brain impaired CVR for such lesions indicates adjustment of healthy blood 
vessels, ie. dropping vascular resistance in order to compete for adequate blood flow supply. 
Subsequently, with a known increased intralesional Oxygen Extraction Fraction (OEF), 
intralesional CVR should theoretically be higher as compared to the whole brain CVR, as 
there should be a higher deoxyhemoglobin content present. With an adequate vasodilatory 
response to a vasodilatory stimulus, the potential wash-out of deoxyhemoglobin is increased 
leading to a higher CVR. However, our findings show a more severely impaired intralesional 
CVR, which makes us believe that the vasodilatory capacity has a much larger effect on the 
BOLD signal intralesional. 
Ideally a multimodal MR imaging protocol, including OEF  and CBF measurements, might 
better explain the underlying pathophysiology.  
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Lastly, impaired CVR was also found within the perifocal edema. A report by Ludemann et 
al. (22) showed that the presence of perifocal edema does not influence CVR measurements 
obtained with BOLD fMRI, but this finding was based on a small cohort and has not been 
reproduced. Although we believe that edema may have contributed to perilesional CVR 
impairment, the fact that intralesional CVR was more severely impaired as compared to as 
well as whole brain CVR were resp. more and equally impaired shows that this effect may not 
be significant. The true influence of edema on perilesional CVR will have to be further 
studied with more detailed analyses.  
 
4.1 Obtaining CVR measurements 
The major challenge for quantifying CVR is the inherent limitation of applying a standardized 
(vaso)active stimulus in order to reliably and sensitively detect CVR abnormalities. (13) Most 
studies therefore determine breath-hold based CVR to assess impaired (peri-)lesional CVR by 
comparing CVR values to the assumingly healthy contralateral hemisphere. 
(7,12,21,22,24,25) Our data, however, demonstrate that quantitative CVR measurements also 
reveal substantially impaired CVR in the contralateral hemisphere. A finding that has been 
confirmed recently by Sam et al. (26) using the same technique. Therefore, breath-hold based 
CVR calculations may lead to type II statistical error.  
For over ten years, we have been successfully employing standardized prospective CO2 
targeting for our BOLD related CVR studies (27,28) and have implemented the same protocol 
for this study with improved methodological CVR analysis. (16) This has resulted in a 
quantitative and sensitive (voxel-wise) whole brain CVR analysis in patients with diffuse 
gliomas. The use of a `healthy` contralateral hemisphere or ROI may also be argued based on 
these data, since all of our subjects exhibited impaired CVR contralaterally. Although a 
relative CVR difference may be calculated from a contralateral hemisphere or ROI, using the 
term healthy may be erroneous. A comparison against a statistical control atlas containing 
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data of healthy volunteers may therefore provide a more sensitive and reliable quantitative 
measure to assess the degree of CVR impairment. (29) 
 
4.2 Limitations  
Theoretically, impaired CVR may have been the consequence of a `dampened` BOLD 
response by CO2 elevations or raised intracranial pressure (ICP) as a result of tumor mass 
including perifocal edema. (23,30) Although the CVR findings appear to discriminate 
between patients with diffuse glioma and healthy controls, possible confounders such as co-
morbidities and glioma characteristics, might have influenced CVR readings. Even though 
these features did not demonstrate a statistically significant effect, these analyses are 
underpowered to reveal possible statistical differences in our cohort, with a relatively small 
sample size of 24 subjects. In addition, the effect of age, pulmonary disease and history of 
chronic cigarette smoking, which may ordinarily increase the arterial to end-tidal gradient in 
spontaneously breathing subjects, might influence CVR readings. However, Ito et al. (31) 
have argued that, with computer controlled prospective end-tidal targeting, the gradient will 
nevertheless, be small, even in the presence of lung disease, over a large range of induced 
PCO2 and O2 pressure. 
 
5. Conclusion 
Patients with brain diffuse glioma exhibit intralesional and whole brain impaired CVR with 
severity correlating to tumor volume. A quantitative whole brain CVR evaluation may have a 
complementary role to better assess BOLD associated neurovascular uncoupling.  
 
Acknowledgments 
We would like to express our gratitude to the Neuro-MRI team of the University Hospital 
Zurich for their support and coordination. None of the authors report conflicts of interest or 
14 
 
will gain financially from this manuscript. This work was supported with the University of 
Zurich `Filling-the-Gap 2015` and `Forschungskredit: Postdoc 2016` initiative.  
 
 
 
 
 
 
6. Reference list  
1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359(5):492-507. 
2. Huang RY, Neagu MR, Reardon DA, Wen PY. Pitfalls in the neuroimaging of glioblastoma in 
the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining 
response. Front Neurol 2015;6:33. 
3. Chung C, Metser U, Menard C. Advances in Magnetic Resonance Imaging and Positron 
Emission Tomography Imaging for Grading and Molecular Characterization of Glioma. Semin 
Radiat Oncol 2015;25(3):164-171. 
4. Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougere C, Pope W, 
Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC. Response 
Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology 
recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 
2016;18(9):1199-1208. 
5. Brugniaux JV, Hodges AN, Hanly PJ, Poulin MJ. Cerebrovascular responses to altitude. 
Respiratory physiology & neurobiology 2007;158(2-3):212-223. 
6. Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA. Glial and neuronal 
control of brain blood flow. Nature 2010;468(7321):232-243. 
7. Pillai JJ, Mikulis DJ. Cerebrovascular Reactivity Mapping: An Evolving Standard for Clinical 
Functional Imaging. AJNR American journal of neuroradiology 2015;36(1):7-13. 
8. Zaca D, Hua J, Pillai JJ. Cerebrovascular reactivity mapping for brain tumor presurgical 
planning. World journal of clinical oncology 2011;2(7):289-298. 
9. Holodny AI, Schulder M, Liu WC, Maldjian JA, Kalnin AJ. Decreased BOLD functional MR 
activation of the motor and sensory cortices adjacent to a glioblastoma multiforme: 
implications for image-guided neurosurgery. AJNR Am J Neuroradiol 1999;20(4):609-612. 
10. Hou BL, Bradbury M, Peck KK, Petrovich NM, Gutin PH, Holodny AI. Effect of brain tumor 
neovasculature defined by rCBV on BOLD fMRI activation volume in the primary motor cortex. 
NeuroImage 2006;32(2):489-497. 
11. Wang Q, Zhang H, Zhang J, Wu C, Zhu W, Li F, Chen X, Xu B. The diagnostic performance of 
magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic 
review and meta-analysis. European radiology 2015. 
12. Hsu YY, Chang CN, Jung SM, Lim KE, Huang JC, Fang SY, Liu HL. Blood oxygenation level-
dependent MRI of cerebral gliomas during breath holding. Journal of magnetic resonance 
imaging : JMRI 2004;19(2):160-167. 
13. Fierstra J, Sobczyk O, Battisti-Charbonney A, Mandell DM, Poublanc J, Crawley AP, Mikulis 
DJ, Duffin J, Fisher JA. Measuring cerebrovascular reactivity: what stimulus to use? The 
Journal of physiology 2013;591(Pt 23):5809-5821. 
14. Mutch WA, Mandell DM, Fisher JA, Mikulis DJ, Crawley AP, Pucci O, Duffin J. Approaches to 
brain stress testing: BOLD magnetic resonance imaging with computer-controlled delivery of 
carbon dioxide. PloS one 2012;7(11):e47443. 
15 
 
15. Slessarev M, Han J, Mardimae A, Prisman E, Preiss D, Volgyesi G, Ansel C, Duffin J, Fisher 
JA. Prospective targeting and control of end-tidal CO2 and O2 concentrations. The Journal of 
physiology 2007;581(Pt 3):1207-1219. 
16. Fierstra J, van Niftrik B, Piccirelli M, Burkhardt JK, Pangalu A, Kocian R, Valavanis A, Weller 
M, Regli L, Bozinov O. Altered intraoperative cerebrovascular reactivity in brain areas of high-
grade glioma recurrence. Magnetic resonance imaging 2016;34(6):803-808. 
17. Liu WC, Feldman SC, Schulder M, Kalnin AJ, Holodny AI, Zimmerman A, Sinensky R, Rao S. 
The effect of tumour type and distance on activation in the motor cortex. Neuroradiology 
2005;47(11):813-819. 
18. Pillai JJ, Zaca D. Comparison of BOLD cerebrovascular reactivity mapping and DSC MR 
perfusion imaging for prediction of neurovascular uncoupling potential in brain tumors. 
Technology in cancer research & treatment 2012;11(4):361-374. 
19. Pillai JJ, Zaca D. Relative utility for hemispheric lateralization of different clinical fMRI 
activation tasks within a comprehensive language paradigm battery in brain tumor patients as 
assessed by both threshold-dependent and threshold-independent analysis methods. 
NeuroImage 2011;54 Suppl 1:S136-145. 
20. Southwell DG, Hervey-Jumper SL, Perry DW, Berger MS. Intraoperative mapping during 
repeat awake craniotomy reveals the functional plasticity of adult cortex. J Neurosurg 
2016;124(5):1460-1469. 
21. Chow DS, Horenstein CI, Canoll P, Lignelli A, Hillman EM, Filippi CG, Grinband J. 
Glioblastoma Induces Vascular Dysregulation in Nonenhancing Peritumoral Regions in 
Humans. AJR American journal of roentgenology 2016;206(5):1073-1081. 
22. Ludemann L, Forschler A, Grieger W, Zimmer C. BOLD signal in the motor cortex shows a 
correlation with the blood volume of brain tumors. J Magn Reson Imaging 2006;23(4):435-443. 
23. Sharma D, Bithal PK, Dash HH, Chouhan RS, Sookplung P, Vavilala MS. Cerebral 
autoregulation and CO2 reactivity before and after elective supratentorial tumor resection. J 
Neurosurg Anesthesiol 2010;22(2):132-137. 
24. Iranmahboob A, Peck KK, Brennan NP, Karimi S, Fisicaro R, Hou B, Holodny AI. Vascular 
Reactivity Maps in Patients with Gliomas Using Breath-Holding BOLD fMRI. Journal of 
neuroimaging : official journal of the American Society of Neuroimaging 2015. 
25. Ben Bashat D, Artzi M, Ben Ami H, Aizenstein O, Blumenthal DT, Bokstein F, Corn BW, Ram 
Z, Kanner AA, Lifschitz-Mercer B, Solar I, Kolatt T, Palmon M, Edrei Y, Abramovitch R. 
Hemodynamic response imaging: a potential tool for the assessment of angiogenesis in brain 
tumors. PloS one 2012;7(11):e49416. 
26. Sam K, Poublanc J, Sobczyk O, Han JS, Battisti-Charbonney A, Mandell DM, Tymianski M, 
Crawley AP, Fisher JA, Mikulis DJ. Assessing the effect of unilateral cerebral revascularisation 
on the vascular reactivity of the non-intervened hemisphere: a retrospective observational 
study. BMJ open 2015;5(2):e006014. 
27. Fierstra J, Conklin J, Krings T, Slessarev M, Han JS, Fisher JA, Terbrugge K, Wallace MC, 
Tymianski M, Mikulis DJ. Impaired peri-nidal cerebrovascular reserve in seizure patients with 
brain arteriovenous malformations. Brain : a journal of neurology 2011;134(Pt 1):100-109. 
28. Spano VR, Mandell DM, Poublanc J, Sam K, Battisti-Charbonney A, Pucci O, Han JS, 
Crawley AP, Fisher JA, Mikulis DJ. CO2 blood oxygen level-dependent MR mapping of 
cerebrovascular reserve in a clinical population, safety, tolerability, and technical feasibility. 
Radiology 2013;266:592-598. 
29. Sobczyk O, Battisti-Charbonney A, Poublanc J, Crawley AP, Sam K, Fierstra J, Mandell DM, 
Mikulis DJ, Duffin J, Fisher JA. Assessing cerebrovascular reactivity abnormality by 
comparison to a reference atlas. Journal of cerebral blood flow and metabolism : official 
journal of the International Society of Cerebral Blood Flow and Metabolism 2014. 
30. Fuchtemeier M, Leithner C, Offenhauser N, Foddis M, Kohl-Bareis M, Dirnagl U, Lindauer U, 
Royl G. Elevating intracranial pressure reverses the decrease in deoxygenated hemoglobin 
and abolishes the post-stimulus overshoot upon somatosensory activation in rats. Neuroimage 
2010;52(2):445-454. 
31. Ito S, Mardimae A, Han J, Duffin J, Wells G, Fedorko L, Minkovich L, Katznelson R, Meineri 
M, Arenovich T, Kessler C, Fisher JA. Non-invasive prospective targeting of arterial P(CO2) in 
subjects at rest. J Physiol 2008;586(Pt 15):3675-3682. 
 
 
 
16 
 
 
 
 
 
 
 
 
 
Figure 1: Illustrative example of cerebrovascular reactivity map and tumor mask 
Caption: Axial projected T1-weighted images demonstrating a glioblastoma WHO grade IV 
in the left frontal region (left upper images, non-contrast and contrast-enhanced T1-weighted 
images) which was subsequently masked by a staff neuroradiologist (A.P.; lower left image), 
to determine CVR in that region (far right images). The tumor masked was subsequently 
flipped in order to determine contralateral CVR in the same region. A separate edema mask 
was created to specifically measure CVR in that region (the tumor mask was subtracted from 
the edema mask to determine CVR in the edema region). CVR ranges from normal reactivity 
(red) to impaired reactivity (yellow-green) to steal phenomenon (blue).  
  
Figure 2: Exemplary cases demonstrating severity of cerebrovascular reactivity 
impairment 
Caption: Axial projected T1-weighted anatomical images and subsequent CVR overlays 
showing a CVR map of a healthy subject (A), and two patients with diffuse glioma (B & C). 
Note that the larger tumor lesion (C) exhibits more severely impaired CVR extending over the 
entire brain. CVR ranges from normal reactivity (red) to impaired reactivity (yellow-green) to 
steal phenomenon (blue).  
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Figure 3: Boxplots of CVR findings in healthy subjects and diffuse glioma patients 
Box-whisker plots of whole brain CVR, intralesional CVR and CVR measured in perilesional 
edema (Figure 3A). On the left is whole brain CVR derived from 12 healthy subjects 
depicted, as a reference. All three aforementioned CVR values (tumor whole brain, 
intralesional and edema) are significantly lower as compared to the healthy CVR (indicated 
with * * *; p<0.01). CVR intralesional as well as CVR edema are also significantly lower as 
compared to whole brain tumor CVR (p<0.05). Figure 3B shows a significantly lower CVR 
for the tumor mask as compared to the same masked flipped onto the contralateral hemisphere 
(p<0.05).  
  
Figure 4: Correlation between cerebrovascular reactivity impairment and tumor volume 
Caption: Graphic representation of the tumor volume plotted versus degree of CVR 
impairment for whole brain (A) and intralesional CVR (B). Both analyses showed a 
significant correlation (p<0.05, R
2
= 0.80 and p<0.05, R
2
 = 0.50, respectively). The dotted red 
line in Figure 4A indicates normal mean quantitative CVR calculated from the 12 healthy 
subjects.  
Abbreviations: WB = whole brain 
 
Supplementary material  
Caption: Supporting Video S1illustrates whole brain normal CVR. Supporting Video S2 
illustrates whole brain impaired CVR in a patient with diffuse glioma (specifically a butterfly 
glioblastoma WHO Grad IV). CVR ranges from normal reactivity (red) to impaired reactivity 
(yellow-green) to steal phenomenon (blue). 
 
Table 1: Patient and tumor characteristics 
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Table 2: CVR findings and tumor volume 
  
CVR (% BOLD signal change/ mmHg CO2) 
Subject 
 Whole 
brain 
Affected 
hemisphere 
Unaffected 
hemisphere intralesional 
Volume 
(cm3) 
1 0.17 0.16 0.18 0.04 47.06 
2 0.22 0.22 0.22 0.17 14.76 
3 0.17 0.13 0.17 0.02 7.79 
4 0.23 0.23 0.25 0.06 2.62 
5 -0.08 -0.09 -0.05 -0.06 144.69 
6 -0.01 -0.02 0.03 -0.07 51.76 
7 0.01 -0.01 0.02 -0.04 119.4 
8 0.1 0.1 0.08 0.02 17.6 
9 0.18 0.1 0.14 0.03 43 
10 0.2 0.16 0.23 0.12 28.55 
11 0.13 0.11 0.14 0.05 77.22 
12 0.04 0.09 0.1 0.01 40.44 
Mean(± SD) 
0.11 (0.10) 0.10 (0.10) 0.13 (0.09) 0.03 (0.07) 
49.57 
(0.16) 
 
Subject Age Sex Histology WHO Grade Tumor location  Clinical presentation CO2 baseline (calibrated) CO2 Hypercapnia
1 49 F Oligoastrocytoma III right frontal Epilepsy 39 48
2 39 M Oligoastrocytoma III left frontal Epilepsy 42 49
3 54 F Oligoastrocytoma III left frontal Headache, aphasia 41 51
4 32 F Anaplastic astrocytoma III right temporal Headache 41 51
5 50 M Oligodendroglioma III bifrontal Headache, Neuropsychological deficits 42 52
6 27 M Astrocytoma III right frontal Epilepsy 41 50
7 66 M Glioblastoma IV bifrontal Neuropsychological deficits 38 49
8 81 M Glioblastoma IV left temporal Aphasia 40 50
9 64 M Glioblastoma IV bifrontal Headache, Neuropsychological deficits 40 51
10 64 F Glioblastoma IV left parieto-occip Epilepsy, hemianopsia 40 50
11 91 M Glioblastoma IV right temporal Headache, vertigo 40 50
12 78 M Glioblastoma IV left frontal Psychomotoric deficits 40 50
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